speb/financial-data huggingface dataset:
RGEN balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 1985483000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 25494000.00
RGEN income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 77801000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 21895000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Current Assets: 1032465000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 15154000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 15154000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 21209000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 21209000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 151996000.00
RGEN cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: -1204000.00
RGEN cash_flow (quarterly, 2025-03-31) — Deferred Tax: -1204000.00
RGEN cash_flow (quarterly, 2025-03-31) — Depreciation: 23188000.00
RGEN cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 23188000.00
RGEN cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 23188000.00
RGEN income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 56558072.00
RGEN income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.10
RGEN income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 5830000.00
RGEN income_statement (quarterly, 2025-03-31) — EBIT: 13193000.00
RGEN income_statement (quarterly, 2025-03-31) — EBITDA: 36381000.00
RGEN cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 4007000.00
RGEN cash_flow (quarterly, 2025-03-31) — End Cash Position: 697229000.00
RGEN cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -5030000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Finished Goods: 63824000.00
RGEN cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 10575000.00
RGEN cash_flow (quarterly, 2025-03-31) — Gain Loss On Investment Securities: 8223000.00
RGEN cash_flow (quarterly, 2025-03-31) — Gain Loss On Sale Of Business: 0.00
RGEN cash_flow (quarterly, 2025-03-31) — Gain Loss On Sale Of PPE: 1218000.00
RGEN income_statement (quarterly, 2025-03-31) — Gain On Sale Of Business: 0.00
RGEN income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: 7314000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -47841000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Goodwill: 1082413000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 1491638000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 149526000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Gross PPE: 497138000.00
RGEN income_statement (quarterly, 2025-03-31) — Gross Profit: 91371000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Income Tax Payable: 1236000.00
RGEN income_statement (quarterly, 2025-03-31) — Interest Expense: 5250000.00
RGEN income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 5250000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Inventory: 153110000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Invested Capital: 2515088000.00
RGEN cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -74108000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 861000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Leases: 148634000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 138939000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 529605000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 668544000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 56208000.00
RGEN cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: -69720000.00
RGEN cash_flow (quarterly, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -8207000.00
RGEN income_statement (quarterly, 2025-03-31) — Net Income: 5830000.00
RGEN income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 5830000.00
RGEN income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 5830000.00
RGEN income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 5830000.00
RGEN income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 5830000.00
RGEN cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 5830000.00
RGEN income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 5830000.00
RGEN income_statement (quarterly, 2025-03-31) — Net Interest Income: -5663000.00
RGEN cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 0.00
RGEN income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -5663000.00
RGEN cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -6494000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Net PPE: 325190000.00
RGEN cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -3521000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 493845000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 737000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 24136000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 737000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 24136000.00
RGEN income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 31040000.00
RGEN income_statement (quarterly, 2025-03-31) — Normalized Income: 1909706.00
RGEN cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 15005000.00
RGEN cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: -8207000.00
RGEN income_statement (quarterly, 2025-03-31) — Operating Income: 8551000.00
RGEN income_statement (quarterly, 2025-03-31) — Operating Revenue: 169172000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 56179127.00
RGEN balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 34713000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 42053000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: -47841000.00
RGEN income_statement (quarterly, 2025-03-31) — Other Income Expense: 5055000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 409225000.00
RGEN cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 14514000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 2113000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 21984000.00
RGEN income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: -286000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Other Properties: 265238000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Payables: 28171000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 50066000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 23514000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 0.00
RGEN income_statement (quarterly, 2025-03-31) — Pretax Income: 7943000.00
RGEN cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 1464000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
RGEN cash_flow (quarterly, 2025-03-31) — Purchase Of Business: -69720000.00
RGEN cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: 0.00
RGEN cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -3563000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Raw Materials: 83251000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Receivables: 147413000.00
RGEN income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 77801000.00
RGEN income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 23188000.00
RGEN income_statement (quarterly, 2025-03-31) — Research And Development: 12114000.00
RGEN income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: 1973000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 413184000.00
RGEN cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 0.00
RGEN cash_flow (quarterly, 2025-03-31) — Sale Of PPE: 42000.00
RGEN income_statement (quarterly, 2025-03-31) — Selling General And Administration: 70706000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Share Issued: 56179127.00
RGEN income_statement (quarterly, 2025-03-31) — Special Income Charges: -1973000.00
RGEN cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 7273000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 1985483000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 493845000.00
RGEN income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 1420706.00
RGEN income_statement (quarterly, 2025-03-31) — Tax Provision: 2113000.00
RGEN income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.27
RGEN balance_sheet (quarterly, 2025-03-31) — Total Assets: 2852143000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 2515088000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Total Debt: 683698000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 1985483000.00
RGEN income_statement (quarterly, 2025-03-31) — Total Expenses: 160621000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 866660000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 1819678000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 714664000.00
RGEN income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 6578000.00
RGEN income_statement (quarterly, 2025-03-31) — Total Other Finance Cost: 413000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 1236000.00
RGEN income_statement (quarterly, 2025-03-31) — Total Unusual Items: 5341000.00
RGEN income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 5341000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Work In Process: 6035000.00
RGEN balance_sheet (quarterly, 2025-03-31) — Working Capital: 880469000.00
RGEN income_statement (quarterly, 2025-06-30) — +Operating Expense: 85185000.00
RGEN income_statement (quarterly, 2025-06-30) — +Total Revenue: 182366000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 25625000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 156952000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Accumulated Depreciation: -183641000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 1634844000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Allowance For Doubtful Accounts Receivable: -2197000.00
RGEN income_statement (quarterly, 2025-06-30) — Basic Average Shares: 56234399.00
RGEN income_statement (quarterly, 2025-06-30) — Basic EPS: 0.26
RGEN cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 697229000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Buildings And Improvements: 763000.00
RGEN cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -7605000.00
RGEN cash_flow (quarterly, 2025-06-30) — Capital Expenditure Reported: -504000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 152339000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Capital Stock: 563000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 708855000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 708855000.00
RGEN cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -10131000.00
RGEN cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -7839000.00
RGEN cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 28609000.00
RGEN cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -1584000.00
RGEN cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: -4802000.00
RGEN cash_flow (quarterly, 2025-06-30) — Change In Inventory: 3004000.00
RGEN cash_flow (quarterly, 2025-06-30) — Change In Other Current Assets: -345000.00
RGEN cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: -5187000.00
RGEN cash_flow (quarterly, 2025-06-30) — Change In Payable: -1584000.00
RGEN cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -6386000.00
RGEN cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 2015000.00
RGEN cash_flow (quarterly, 2025-06-30) — Change In Receivables: -5237000.00
RGEN cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -12136000.00
RGEN cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: -5237000.00
RGEN cash_flow (quarterly, 2025-06-30) — Changes In Cash: 10639000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Common Stock: 563000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 2061741000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Construction In Progress: 25943000.00
RGEN income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 91224000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 18250000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Current Assets: 1056865000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 16043000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 16043000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 20806000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 20806000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 123012000.00
RGEN cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: -1365000.00
RGEN cash_flow (quarterly, 2025-06-30) — Deferred Tax: -1365000.00
RGEN cash_flow (quarterly, 2025-06-30) — Depreciation: 24766000.00
RGEN cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 24766000.00
RGEN cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 24766000.00
RGEN income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 56510323.00
RGEN income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.26
RGEN income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 14866000.00
RGEN income_statement (quarterly, 2025-06-30) — EBIT: 23569000.00
RGEN income_statement (quarterly, 2025-06-30) — EBITDA: 48335000.00
RGEN cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 987000.00
RGEN cash_flow (quarterly, 2025-06-30) — End Cash Position: 708855000.00
RGEN cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -10131000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Finished Goods: 71001000.00
RGEN cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 21004000.00
RGEN cash_flow (quarterly, 2025-06-30) — Gain Loss On Investment Securities: 486000.00
RGEN cash_flow (quarterly, 2025-06-30) — Gain Loss On Sale Of PPE: 2164000.00
RGEN income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: 6585000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -1716000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Goodwill: 1114009000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 1520222000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Gross Accounts Receivable: 159149000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Gross PPE: 504812000.00
RGEN income_statement (quarterly, 2025-06-30) — Gross Profit: 91142000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Income Tax Payable: 1408000.00
RGEN income_statement (quarterly, 2025-06-30) — Interest Expense: 5354000.00
RGEN income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 5354000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Inventory: 155862000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Invested Capital: 2595466000.00
RGEN cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -7839000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Land And Improvements: 917000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Leases: 149832000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 136296000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 533725000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 670021000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Machinery Furniture Equipment: 58514000.00
RGEN cash_flow (quarterly, 2025-06-30) — Net Business Purchase And Sale: -234000.00
RGEN cash_flow (quarterly, 2025-06-30) — Net Foreign Currency Exchange Gain Loss: -4046000.00
RGEN income_statement (quarterly, 2025-06-30) — Net Income: 14866000.00
RGEN income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 14866000.00
RGEN income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 14866000.00
RGEN income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 14866000.00
RGEN income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 14866000.00
RGEN cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 14866000.00
RGEN income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 14866000.00
RGEN income_statement (quarterly, 2025-06-30) — Net Interest Income: -5768000.00
RGEN income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -5768000.00
RGEN cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: -10131000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Net PPE: 321171000.00
RGEN cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -7101000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 541519000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 800000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 23326000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 800000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 23326000.00
RGEN income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 33811000.00
RGEN income_statement (quarterly, 2025-06-30) — Normalized Income: 3014416.00
RGEN cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 28609000.00
RGEN cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: 8045000.00
RGEN income_statement (quarterly, 2025-06-30) — Operating Income: 5957000.00
RGEN income_statement (quarterly, 2025-06-30) — Operating Revenue: 182366000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 56253009.00
RGEN balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 35196000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 14355000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -1716000.00
RGEN income_statement (quarterly, 2025-06-30) — Other Income Expense: 18026000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 406213000.00
RGEN cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: -13942000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 2569000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 23527000.00
RGEN income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 3502000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Other Properties: 268843000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Payables: 27033000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 45283000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 26525000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 0.00
RGEN income_statement (quarterly, 2025-06-30) — Pretax Income: 18215000.00
RGEN cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 0.00
RGEN balance_sheet (quarterly, 2025-06-30) — Properties: 0.00
RGEN cash_flow (quarterly, 2025-06-30) — Purchase Of Business: -234000.00
RGEN cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -7101000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Raw Materials: 78157000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Receivables: 156952000.00
RGEN income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 91224000.00
RGEN income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 24766000.00
RGEN income_statement (quarterly, 2025-06-30) — Research And Development: 13958000.00
RGEN income_statement (quarterly, 2025-06-30) — Restructuring And Mergern Acquisition: -7939000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Retained Earnings: 428050000.00
RGEN cash_flow (quarterly, 2025-06-30) — Sale Of PPE: 0.00
RGEN income_statement (quarterly, 2025-06-30) — Selling General And Administration: 71227000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Share Issued: 56253009.00
RGEN income_statement (quarterly, 2025-06-30) — Special Income Charges: 7939000.00
RGEN cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 8375000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 2061741000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 541519000.00
RGEN income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 2672416.00
RGEN income_statement (quarterly, 2025-06-30) — Tax Provision: 3349000.00
RGEN income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.18
RGEN balance_sheet (quarterly, 2025-06-30) — Total Assets: 2901627000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 2595466000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Total Debt: 686064000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 2061741000.00
RGEN income_statement (quarterly, 2025-06-30) — Total Expenses: 176409000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 839886000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 1844762000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 716874000.00
RGEN income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: 13896000.00
RGEN income_statement (quarterly, 2025-06-30) — Total Other Finance Cost: 414000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 1408000.00
RGEN income_statement (quarterly, 2025-06-30) — Total Unusual Items: 14524000.00
RGEN income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 14524000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Work In Process: 6704000.00
RGEN balance_sheet (quarterly, 2025-06-30) — Working Capital: 933853000.00
RGEN income_statement (quarterly, 2025-09-30) — +Operating Expense: 87838000.00
RGEN income_statement (quarterly, 2025-09-30) — +Total Revenue: 188805000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 29426000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 148970000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -193584000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 1643670000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Allowance For Doubtful Accounts Receivable: -2274000.00
RGEN income_statement (quarterly, 2025-09-30) — Basic Average Shares: 56265000.00
RGEN income_statement (quarterly, 2025-09-30) — Basic EPS: 0.27
RGEN cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 708855000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Buildings And Improvements: 763000.00
RGEN cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -5386000.00
RGEN cash_flow (quarterly, 2025-09-30) — Capital Expenditure Reported: -684000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 150940000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Capital Stock: 563000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 748747000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 748747000.00
RGEN cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -239000.00
RGEN cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -7783000.00
RGEN cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 48099000.00
RGEN cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 3194000.00
RGEN cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: 12624000.00
RGEN cash_flow (quarterly, 2025-09-30) — Change In Inventory: -4522000.00
RGEN cash_flow (quarterly, 2025-09-30) — Change In Other Current Assets: -180000.00
RGEN cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -1655000.00
RGEN cash_flow (quarterly, 2025-09-30) — Change In Payable: 3194000.00
RGEN cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 15818000.00
RGEN cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -5318000.00
RGEN cash_flow (quarterly, 2025-09-30) — Change In Receivables: 7856000.00
RGEN cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 11999000.00
RGEN cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: 7856000.00
RGEN cash_flow (quarterly, 2025-09-30) — Changes In Cash: 40077000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Common Stock: 563000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 2083087000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 25149000.00
RGEN income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 88290000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 22717000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Current Assets: 1096485000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 19314000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 19314000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 15681000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 15681000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 131136000.00
RGEN cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: -3215000.00
RGEN cash_flow (quarterly, 2025-09-30) — Deferred Tax: -3215000.00
RGEN cash_flow (quarterly, 2025-09-30) — Depreciation: 24410000.00
RGEN cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 24410000.00
RGEN cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 24410000.00
RGEN income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 56532000.00
RGEN income_statement (quarterly, 2025-09-30) — Diluted EPS: 0.26
RGEN income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 14911000.00
RGEN income_statement (quarterly, 2025-09-30) — EBIT: 22526000.00
RGEN income_statement (quarterly, 2025-09-30) — EBITDA: 46936000.00
RGEN cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -185000.00
RGEN cash_flow (quarterly, 2025-09-30) — End Cash Position: 748747000.00
RGEN cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -239000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Finished Goods: 72170000.00
RGEN cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 42713000.00
RGEN income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: 6921000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -4107000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Goodwill: 1112735000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 1508177000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Gross Accounts Receivable: 151244000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Gross PPE: 506672000.00
RGEN income_statement (quarterly, 2025-09-30) — Gross Profit: 100515000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Income Tax Payable: 2852000.00
RGEN income_statement (quarterly, 2025-09-30) — Interest Expense: 5414000.00
RGEN income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 5414000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Inventory: 160320000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Invested Capital: 2621014000.00
RGEN cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -7783000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Land And Improvements: 908000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Leases: 150168000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 131626000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 537927000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 669553000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 60674000.00
RGEN cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: 0.00
RGEN cash_flow (quarterly, 2025-09-30) — Net Foreign Currency Exchange Gain Loss: -190000.00
RGEN income_statement (quarterly, 2025-09-30) — Net Income: 14911000.00
RGEN income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 14911000.00
RGEN income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 14911000.00
RGEN income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 14911000.00
RGEN income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 14911000.00
RGEN cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 14911000.00
RGEN income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 14911000.00
RGEN income_statement (quarterly, 2025-09-30) — Net Interest Income: -5830000.00
RGEN income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -5830000.00
RGEN cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -917000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Net PPE: 313088000.00
RGEN cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -4702000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 574910000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 856000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 20135000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 856000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 20135000.00
RGEN income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 35867000.00
RGEN income_statement (quarterly, 2025-09-30) — Normalized Income: 5269901.00
RGEN cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 48099000.00
RGEN cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: -12281000.00
RGEN income_statement (quarterly, 2025-09-30) — Operating Income: 12677000.00
RGEN income_statement (quarterly, 2025-09-30) — Operating Revenue: 188805000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 56283321.00
RGEN balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 38448000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 5107000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: -4107000.00
RGEN income_statement (quarterly, 2025-09-30) — Other Income Expense: 10265000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 395442000.00
RGEN cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 3302000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 5105000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 19800000.00
RGEN income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: -804000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Other Properties: 269010000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Payables: 32278000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 54995000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 36039000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 0.00
RGEN income_statement (quarterly, 2025-09-30) — Pretax Income: 17112000.00
RGEN cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 678000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Properties: 0.00
RGEN cash_flow (quarterly, 2025-09-30) — Purchase Of Business: 0.00
RGEN cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -4702000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Raw Materials: 79312000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Receivables: 148970000.00
RGEN income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 88290000.00
RGEN income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 24410000.00
RGEN income_statement (quarterly, 2025-09-30) — Research And Development: 14175000.00
RGEN income_statement (quarterly, 2025-09-30) — Restructuring And Mergern Acquisition: -4148000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Retained Earnings: 442961000.00
RGEN cash_flow (quarterly, 2025-09-30) — Sale Of PPE: 0.00
RGEN income_statement (quarterly, 2025-09-30) — Selling General And Administration: 73663000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Share Issued: 56283321.00
RGEN income_statement (quarterly, 2025-09-30) — Special Income Charges: 4148000.00
RGEN cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 8973000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 2083087000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 574910000.00
RGEN income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 1427901.00
RGEN income_statement (quarterly, 2025-09-30) — Tax Provision: 2201000.00
RGEN income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.13
RGEN balance_sheet (quarterly, 2025-09-30) — Total Assets: 2923711000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 2621014000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Total Debt: 688867000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 2083087000.00
RGEN income_statement (quarterly, 2025-09-30) — Total Expenses: 176128000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 840624000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 1827226000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 709488000.00
RGEN income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 16825000.00
RGEN income_statement (quarterly, 2025-09-30) — Total Other Finance Cost: 416000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 2852000.00
RGEN income_statement (quarterly, 2025-09-30) — Total Unusual Items: 11069000.00
RGEN income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 11069000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Work In Process: 8838000.00
RGEN balance_sheet (quarterly, 2025-09-30) — Working Capital: 965349000.00
RGEN income_statement (annual, 2025-12-31) — +Operating Expense: 344685000.00
RGEN income_statement (quarterly, 2025-12-31) — +Operating Expense: 87483000.00
RGEN income_statement (annual, 2025-12-31) — +Total Revenue: 738256000.00
RGEN income_statement (quarterly, 2025-12-31) — +Total Revenue: 197913000.00
RGEN balance_sheet (annual, 2025-12-31) — Accounts Payable: 30010000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 30010000.00
RGEN balance_sheet (annual, 2025-12-31) — Accounts Receivable: 158587000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 158587000.00
RGEN balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -203882000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -203882000.00
RGEN balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 1651849000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 1651849000.00
RGEN balance_sheet (annual, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -2767000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -2767000.00
RGEN income_statement (annual, 2025-12-31) — Basic Average Shares: 56234000.00
RGEN income_statement (quarterly, 2025-12-31) — Basic Average Shares: 56310000.00
RGEN income_statement (annual, 2025-12-31) — Basic EPS: 0.87
RGEN income_statement (quarterly, 2025-12-31) — Basic EPS: 0.24
RGEN cash_flow (annual, 2025-12-31) — Beginning Cash Position: 757355000.00
RGEN cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 748747000.00
RGEN balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 763000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 763000.00
RGEN cash_flow (annual, 2025-12-31) — Capital Expenditure: -25730000.00
RGEN cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -8309000.00
RGEN cash_flow (annual, 2025-12-31) — Capital Expenditure Reported: -2211000.00
RGEN cash_flow (quarterly, 2025-12-31) — Capital Expenditure Reported: -156000.00
RGEN balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 147735000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 147735000.00
RGEN balance_sheet (annual, 2025-12-31) — Capital Stock: 563000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Capital Stock: 563000.00
RGEN balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 566021000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 566021000.00
RGEN balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 767628000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 767628000.00
RGEN cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: -15205000.00
RGEN cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 195000.00
RGEN cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -298474000.00
RGEN cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -208744000.00
RGEN cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 117417000.00
RGEN cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 25704000.00
RGEN cash_flow (annual, 2025-12-31) — Change In Account Payable: -4150000.00
RGEN cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 933000.00
RGEN cash_flow (annual, 2025-12-31) — Change In Accrued Expense: 11813000.00
RGEN cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: 2184000.00
RGEN cash_flow (annual, 2025-12-31) — Change In Inventory: -14947000.00
RGEN cash_flow (quarterly, 2025-12-31) — Change In Inventory: -9601000.00
RGEN cash_flow (annual, 2025-12-31) — Change In Other Current Assets: -1560000.00
RGEN cash_flow (quarterly, 2025-12-31) — Change In Other Current Assets: 167000.00
RGEN cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -17115000.00
RGEN cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: -5912000.00
RGEN cash_flow (annual, 2025-12-31) — Change In Payable: -4150000.00
RGEN cash_flow (quarterly, 2025-12-31) — Change In Payable: 933000.00
RGEN cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 7663000.00
RGEN cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 3117000.00
RGEN cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -7756000.00
RGEN cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -2262000.00
RGEN cash_flow (annual, 2025-12-31) — Change In Receivables: -17165000.00
RGEN cash_flow (quarterly, 2025-12-31) — Change In Receivables: -9863000.00
RGEN cash_flow (annual, 2025-12-31) — Change In Working Capital: -50880000.00
RGEN cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -24354000.00
RGEN cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -17165000.00
RGEN cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: -9863000.00
RGEN cash_flow (annual, 2025-12-31) — Changes In Cash: -196262000.00
RGEN cash_flow (quarterly, 2025-12-31) — Changes In Cash: -182845000.00
RGEN balance_sheet (annual, 2025-12-31) — Common Stock: 563000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Common Stock: 563000.00
RGEN balance_sheet (annual, 2025-12-31) — Common Stock Equity: 2106129000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 2106129000.00
RGEN cash_flow (annual, 2025-12-31) — Common Stock Payments: 0.00
RGEN balance_sheet (annual, 2025-12-31) — Construction In Progress: 28401000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 28401000.00
RGEN income_statement (annual, 2025-12-31) — Cost Of Revenue: 352011000.00
RGEN income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 94082000.00
RGEN balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 20866000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 20866000.00
RGEN balance_sheet (annual, 2025-12-31) — Current Assets: 1137385000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Current Assets: 1137385000.00
RGEN balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 21559000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 21559000.00
RGEN balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 21559000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 21559000.00
RGEN balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 14609000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 14609000.00
RGEN balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 14609000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 14609000.00
RGEN balance_sheet (annual, 2025-12-31) — Current Liabilities: 135826000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 135826000.00
RGEN cash_flow (annual, 2025-12-31) — Deferred Income Tax: -3373000.00
RGEN cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: 2411000.00
RGEN cash_flow (annual, 2025-12-31) — Deferred Tax: -3373000.00
RGEN cash_flow (quarterly, 2025-12-31) — Deferred Tax: 2411000.00
RGEN cash_flow (annual, 2025-12-31) — Depreciation: 96956000.00
RGEN cash_flow (quarterly, 2025-12-31) — Depreciation: 24592000.00
RGEN cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 96956000.00
RGEN cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 24592000.00
RGEN cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 96956000.00
RGEN cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 24592000.00
RGEN income_statement (annual, 2025-12-31) — Diluted Average Shares: 56561000.00
RGEN income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 56659000.00
RGEN income_statement (annual, 2025-12-31) — Diluted EPS: 0.86
RGEN income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.23
RGEN income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 48894000.00
RGEN income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 13287000.00
RGEN income_statement (annual, 2025-12-31) — EBIT: 83896000.00
RGEN income_statement (quarterly, 2025-12-31) — EBIT: 24608000.00
RGEN income_statement (annual, 2025-12-31) — EBITDA: 180852000.00
RGEN income_statement (quarterly, 2025-12-31) — EBITDA: 49200000.00
RGEN cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 4928000.00
RGEN cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 119000.00
RGEN cash_flow (annual, 2025-12-31) — End Cash Position: 566021000.00
RGEN cash_flow (quarterly, 2025-12-31) — End Cash Position: 566021000.00
RGEN cash_flow (annual, 2025-12-31) — Financing Cash Flow: -15205000.00
RGEN cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 195000.00
RGEN balance_sheet (annual, 2025-12-31) — Finished Goods: 55033000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Finished Goods: 55033000.00
RGEN cash_flow (annual, 2025-12-31) — Free Cash Flow: 91687000.00
RGEN cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 17395000.00
RGEN income_statement (annual, 2025-12-31) — Gain On Sale Of Security: 27574000.00
RGEN income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: 6754000.00
RGEN balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -2531000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -2531000.00
RGEN balance_sheet (annual, 2025-12-31) — Goodwill: 1114408000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Goodwill: 1114408000.00
RGEN balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 1500555000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 1500555000.00
RGEN balance_sheet (annual, 2025-12-31) — Gross Accounts Receivable: 161354000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Gross Accounts Receivable: 161354000.00
RGEN balance_sheet (annual, 2025-12-31) — Gross PPE: 510034000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Gross PPE: 510034000.00
RGEN income_statement (annual, 2025-12-31) — Gross Profit: 386245000.00
RGEN income_statement (quarterly, 2025-12-31) — Gross Profit: 103831000.00
RGEN balance_sheet (annual, 2025-12-31) — Income Tax Payable: 3592000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Income Tax Payable: 3592000.00
RGEN income_statement (annual, 2025-12-31) — Interest Expense: 21513000.00
RGEN income_statement (quarterly, 2025-12-31) — Interest Expense: 5495000.00
RGEN income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 21513000.00
RGEN income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 5495000.00
RGEN balance_sheet (annual, 2025-12-31) — Inventory: 170458000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Inventory: 170458000.00
RGEN balance_sheet (annual, 2025-12-31) — Invested Capital: 2648342000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Invested Capital: 2648342000.00
RGEN cash_flow (annual, 2025-12-31) — Investing Cash Flow: -298474000.00
RGEN cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -208744000.00
RGEN cash_flow (annual, 2025-12-31) — Issuance Of Debt: 0.00
RGEN balance_sheet (annual, 2025-12-31) — Land And Improvements: 564000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 564000.00
RGEN balance_sheet (annual, 2025-12-31) — Leases: 151121000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Leases: 151121000.00
RGEN balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 126176000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 126176000.00
RGEN balance_sheet (annual, 2025-12-31) — Long Term Debt: 542213000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 542213000.00
RGEN balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 668389000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 668389000.00
RGEN cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 0.00
RGEN cash_flow (annual, 2025-12-31) — Long Term Debt Payments: 0.00
RGEN cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: 0.00
RGEN balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 61697000.00
RGEN balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 61697000.00
RGEN cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -70328000.00
RGEN cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: -374000.00
RGEN cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 0.00
RGEN income_statement (annual, 2025-12-31) — Net Income: 48894000.00
RGEN income_statement (quarterly, 2025-12-31) — Net Income: 13287000.00